FDA Increases Flexibility on Requirements for Cell and Gene Therapies to Advance Innovation
White Oak, Md., Jan. 12, 2026 (GLOBE NEWSWIRE) — The U.S. Food and Drug Administration today announced it is sharing information about the agency's flexible approach to overseeing chemistry, manufacturing and control (CMC) requirements for cell and gene therapies (CGT). The agency's more flexible approach has been, and is expected to continue to be, helpful […]